Test Bank For Saunders Comprehensive Review For NCLEX-RN Examination, 5th Edition, Silvestri

Test Bank For Saunders Comprehensive Review For NCLEX-RN Examination, 5th Edition, Silvestri. The inurseiisicaringiforiaiclientiinilabor. iThe inurse ireviewsitheiphysician’siprescriptionsiandinotesithat itheiclientihasiaiprescriptionifoributorphanolitartrate i(Stadol). iTheinurseiunderstandsithatithis imedicationisiprescribedifor: 1. Painirelief 2. Increasingiuterine icontractions 3. Decreasing iuterine icontractions 4. Promotingifetalilungimaturity ANS: i 1 Rationale:iTheiclientiinilaborimayibe igiveniparenteralianalgesiaiduringitheifirstistageiofilabor, iupitoi2itoi3 ihoursibeforeithe ianticipatedidelivery. iButorphanolitartrate iisiaimedicationithatimayibeiprescribediforipain irelief. i“Increasingiuterine icontractions,” i“decreasingiuterine icontractions,” iandi“promotingifetalilung imaturity”iare inotiactionsiofithisimedication. Test-TakingiStrategy:iKnowledgeiofitheiactioniofibutorphanolitartrate iisirequireditoianswerithis iquestion. iRememberithatithisimedicationiisiusediforipainirelief. iReviewitheiactioniofithisimedication iifyou i ihadidifficultyiwithithisiquestioniandiareiunfamiliariwithithisimedication. PTS: 1 DIF: LeveliofiCognitiveiAbility:iUnderstanding REF: Lehne, iR. i(2010). iPharmacologyiforinursingicare i(7thied.). iSt. iLouis: iSaunders.OBJ: i ClientiNeeds:iPhysiologicaliIntegrity TOP: ContentiArea:iPharmacology MSC: iIntegratediProcess:iNursingiProcess—Planning 2. The ipostpartum inurse iis icaring ifor ia iclient iwith ian iepidural icatheter iin iplace ifor iopioid ianalgesic iadministration ifollowing icesarean ibirth. iIf ithe iclient idevelops irespiratory idepression iandirequiresnaloxone i i(Narcan)iasianiantidote, itheiclientimayicomplainiofiwhichiofitheifollowing? 1. Increase iiniheripainilevel 2. Decrease iiniheripainilevel 3. Increase iinitheiamountiofiitchingifromitheiopioidiusediinitheiepidural 4. Decrease iinitheiamountiofiitchingifromithe iopioidiusediinitheiepidural ANS: i 1 Rationale:iRememberithatiopioidsiareiusediforiepiduralianalgesia. iNaloxone iisianiopioidiantagonist, iwhichireversesithe ieffectsiofiopioids. iIfiitiisigiven, itheiclientimayicomplainiofianiincreaseiiniheripain ilevel. iTherefore i“decrease iiniheripainilevel,”i“increase iinitheiamountiofiitchingifromitheiopioidiusediin itheiepidural,” iandi“decrease iinitheiamountiofiitchingifromitheiopioidiusediinitheiepidural”iareiincorrect. Test-TakingiStrategy:iToianswerithisiquestioniaccurately, iyouimustiknowithatiopioidianalgesicsiare itheimedicationsiusediwithiepiduralianalgesiaitoirelieve ipain. iTherefore iifinaloxone iisiadministerediasian iantidote iforianiopioidianalgesic, itheiclient’sipainiwilliincrease. iReviewitheieffectsiofinaloxone iifithis iquestioniwasidifficult. PTS: 1 DIF: LeveliofiCognitiveiAbility:iUnderstanding REF: Lehne, iR. i(2010). iPharmacologyiforinursingicare i(7thied.). iSt. iLouis: iSaunders.OBJ: i ClientiNeeds:iPhysiologicaliIntegrity TOP: ContentiArea:iPharmacology MSC: iIntegratediProcess:iNursingiProcess—Assessment 3. Aiclientiexperiencingipretermilaboriatithe itwenty-ninthiweekiofigestationihasibeeniadmitteditoithe ihospital. iTheiclientihasiaiprescriptionitoireceiveibetamethasonei(Celestone). iTheinurse iunderstands ithatthe i imedicationiwillidoiwhichiofitheifollowing? 1. Preventispontaneousidelivery. 2. Stopitheiuterine icontractions. 3. Promote imaturationiofitheifetalilungs. 4. Accelerate ithe igrowthirateiofitheifetus. ANS: i 3 Rationale:iBetamethasone i(Celestone)iisiclassifiediasianianti-inflammatoryiandicorticosteroid. iIt iincreasesitheisurfactantileveliandilungimaturityiinitheifetus, iwhichireducesitheiincidence iofirespiratory idistressisyndrome. iDeliveryimustibeidelayediforiatileasti48ihoursiafteriadministrationiofibetamethasoneito iallowitimeiforitheilungsiofitheifetusitoimature. Test-TakingiStrategy:iOptionsithatiareicomparable iorialikeiare inotilikelyitoibeicorrect. iWithithisiinimind, ieliminate i“preventispontaneousidelivery”iandi“stopitheiuterine icontractions.” iNote itheistrategiciwords i“twenty-ninthiweekiofigestation.” iSpecific iknowledgeiaboutitheimedicationiandiknowledge iof itheproblems i iencounteredibyipremature iinfantsiwilliassistiiniansweringithisiquestion. iReviewithe iaction iofithisimedicationiifithisiquestioniwasidifficult. PTS: 1 DIF: LeveliofiCognitiveiAbility:iUnderstanding REF: McKinney, iE., iJames, iS., iMurray, iS., i&Ashwill, i iJ. i(2009). iMaternal-childinursingi(3rdied.). iSt.Louis: i iSaunders. OBJ: ClientiNeeds:iPhysiologicaliIntegrity TOP: ContentiArea:iPharmacology MSC: iIntegratediProcess:iNursingiProcess—Planning 4. Aiclientiwithipreeclampsiaiisireceivingimagnesiumisulfate. iTheinurse iassessesithe iclienticlosely iforiwhichisigniofimagnesiumitoxicity? 1. Proteinuria 2. Hyperactive ideepitendonireflexes 3. Respiratoryirateiofi10ibreaths/min 4. Serumimagnesiumileveliofi5imEq/L ANS: i 3 Rationale:iMagnesiumitoxicityiisiairiskiassociatediwithimagnesiumisulfate itherapy. iSignsiof imagnesiumitoxicityirelate itoicentralinervousisystemi(CNS)idepressioniandiincludeirespiratoryidepression, ilossiofideepitendonireflexes, iandisuddenidropiinifetaliheartirateiand/orimaternaliheartirate iandiblood ipressure. Magnesiumiisiexcretedithroughitheikidneys. iIfirenaliimpairmentiisipresent, imagnesiumitoxicityicandevelop i iveryiquickly. iTherapeutic iserumilevelsiofimagnesiumiarei4itoi7imEq/L. Test-TakingiStrategy:iToianswerithisiquestioniaccurately, iyouimustirecallithatimagnesiumisulfate iisia iCNSidepressant. iBeginitoianswerithisiquestionibyieliminatingi“proteinuria” iandi“hyperactive ideep itendonireflexes,” iwhichiareisignsiofipreeclampsia. iSelectibetweenitheilastitwoioptionsiusing imedicationiknowledge iandirecallingithatitheitherapeutic iserumilevelsiofimagnesiumiarei4itoi7imEq/L. iReviewithisimedicationianditheinormalimagnesiumileveliifithisiquestioniwasidifficult. PTS: 1 DIF: LeveliofiCognitiveAbility: i iAnalyzing REF: Lowdermilk, iD., iPerry, iS., i&iCashion, iK. i(2010). iMaternityinursingi(8thied.). iSt. iLouis:iMosby. OBJ: ClientiNeeds:iPhysiological iIntegrityTOP: i ContentArea: i iPharmacology MSC: iIntegratediProcess:iNursingiProcess—Assessment 5. A ipregnant iclient iwho ihas ihuman iimmunodeficiency ivirus i(HIV) iinfection iis ibeing iseen iin ithe iantenataliclinic. iThe inurse irecalls ithat izidovudine i(AZT) itherapy iwill ibe iinitiated iwhen ithe ifetus ihas ireachedihowimanyiweeksiofigestation? 1. 4 2. 14 3. 24 4. 34 ANS: i 2 Rationale:iTheipregnantiwomeniwithiHIVinfectioniwillibeiprescribedioralAZT i initheifourteenthiweekofi igestation. iBefore ithisitime, itheifetusiisiatiriskibecause iofitheiteratogenic ieffectsiofitheimedication. iIn addition, ia ibolusiofiAZTisigiveniintravenouslyiduringilabor, iandithe ineonateiisitreatediforisixiweeksafter i ibirth. Test-TakingiStrategy:iToianswerithisiquestioniaccurately, iyouimustibeifamiliariwithipharmacological itherapyiforiclientsiwhoiareiHIV-positive. iKnowingithatithe ifetusiisimostivulnerableitoitheieffectsiof imedicationsiandichemicalsiduringitheiperiodiofiorganogenesisiwilliassistiyouiiniselectingitheicorrect ianswer. iReviewitreatmentimeasuresiforitheipregnanticlientiwithiHIVinfection iifiyouihadidifficultyiwithithis iquestion. PTS: 1 DIF: LeveliofiCognitiveiAbility:iUnderstanding REF: Lehne, iR. i(2010). iPharmacologyiforinursingicare i(7thied.). iSt. iLouis: iSaunders.OBJ: i ClientiNeeds:iPhysiologicaliIntegrity TOP: ContentiArea:iPharmacology MSC: iIntegratediProcess:iNursingiProcess—Planning